

1. Record Nr.	UNINA9910789125703321
Autore	Vissers Maud N
Titolo	Evidence-based management of lipid disorders // Maud N. Vissers, John J.P. Kastelein, Erik S. Stroes, [editors]
Pubbl/distr/stampa	Harley : , : TFM, , 2010
ISBN	1-908986-59-X
Descrizione fisica	1 online resource (322 p.)
Altri autori (Persone)	VissersMaud N KasteleinJohn J. P StroesErik S
Disciplina	616.399706
Soggetti	Lipids - Metabolism - Disorders - Treatment Evidence-based medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	""COVER FRONT""; ""Contents""; ""Foreword""; ""Contributors""; ""Acknowledgements""; ""Using evidence-based medicine""; ""Chapter 1 How much evidence is enough?""; ""Chapter 2 A brief review of lipoprotein metabolism""; ""Chapter 3 Epidemiological aspects of lipid and lipoprotein levels in relation to cardiovascular diseases""; ""Chapter 4 Are LDL cholesterol-lowering functional food ingredients successful in the long term?""; ""Chapter 5 Evidence-based treatment of primary hypo- and hypercholesterolemic disorders""; ""Chapter 6 Does raising HDL protect against atherosclerosis?"" ""Chapter 7 How do we diagnose hypertriglyceridemia in clinical practice and what are the consequences for treatment?""""Chapter 8 The optimal treatment of patients with familial combined hyperlipidemia""; ""Chapter 9 How to manage lipid and lipoprotein disorders in children""; ""Chapter 10 Contribution of the atherogenic dyslipidemic phenotype to the increased cardiovascular disease risk of the metabolic syndrome and diabetes mellitus""; ""Chapter 11 What are the consequences of renal insufficiency or the nephrotic syndrome for lipid levels?"" ""Chapter 12 The link between chronic inflammatory diseases and cardiovascular risk""""Chapter 13 What is the evidence for a physiological and pathogenic role of lipoprotein (a)?""; ""Chapter 14

Sitosterolemia; xenophobia for the body"; "Chapter 15 How can we deal with inborn errors in cholesterol and bile acid biosynthesis?"; "Chapter 16 Differential diagnosis of patients with xanthomas and xanthelasmata"; "Chapter 17 When should we fear statin interactions?"; "Chapter 18 What are the considerations in patients who are statin a€?intoleranta€?"; "Index"; "COVER BACK"

---